+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
All Genders
ID07914764

Research on 68Ga-Labeled CCK2R-Targeted Molecular Probes for Early Tumor Detection Using PET-CT Imaging

Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2026-11-04

20

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new radioactive molecular probe called 68Ga-YQ-CC05 that targets the cholecystokinin receptor CCK2R to assess its safety and effectiveness in detecting tumors. This study focuses on patients with medullary thyroid carcinoma, small cell lung cancer, and gastric adenocarcinoma. The goal is to improve early tumor diagnosis using this targeted imaging method. Participants receive an intravenous injection of the 68Ga-YQ-CC05 imaging agent at a dose of 0.05 mCi per kilogram of body weight. PET-CT scans are then performed 60 minutes after the injection to observe tumor uptake of the probe. This imaging technique is compared to other standard methods such as CT and MRI to verify its diagnostic value. During the study, participants undergo PET-CT imaging and provide pathological results to confirm tumor presence. Researchers measure the maximum standardized uptake value SUVmax of the lesion one hour after administration of the probe to evaluate its effectiveness. The study involves monitoring kidney and liver function, blood counts, and patient safety throughout. Total participation time aligns with the imaging and assessment schedule around the injection and scanning procedures.

CONDITIONS

Brief Title

68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis

Research Team

F

Feng Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here